Fertility Preservation Methods in Breast Cancer

Peccatori, Fedro Alessandro; Pup, Lino Del; Salvagno, Francesca; Guido, Maurizio; Sarno, Maria; Revelli, Alberto; Piane, Luisa Delle; Dolfin, Elisabetta; Franchi, D.; Molinari, Emanuela; Immediata, Valentina; Chiavari, Leonora; Vucetich, A.; Borini, Andrea

doi:10.1159/000339671

Cited by 12 publications

(9 citation statements)

References 61 publications

(55 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…12 Beyond additional choices of adoption and oocyte donation, improvements in assisted reproductive technologies (ART) have allowed options for women to undergo fertility preservation prior to initiation of chemotherapy. 13 Specifically, embryo or oocyte cryopreservation 13 are currently the gold-standard option for fertility preservation in young women with cancer. 14 These methods have shown a live birth rate of 40 % for oocytes and 50 % for embryos.…”

mentioning

confidence: 99%

Fertility in Women of Reproductive Age After Breast Cancer Treatment: Practice Patterns and Outcomes

et al. 2016

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

Fertility in Women of Reproductive Age After Breast Cancer Treatment: Practice Patterns and Outcomes

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Currently a mere 50% of all patients worldwide receive such guidance. As a result, many women start chemotherapy without being aware of the potential loss of fertility [ 39 , 40 ]. This is alarming in view of the fact that approximately one third of all premenopausal breast cancer patients still wish to have children at the time of diagnosis [ 40 ].…”

Section: Discussionmentioning

confidence: 99%

Reduced ovarian reserve in young early breast cancer patients: preliminary data from a prospective cohort trial

et al. 2017

View full text Add to dashboard Cite

BackgroundThe numerous side effects of chemotherapy in patients with breast cancer are well known. However, the precise effects of chemotherapy on ovarian function in premenopausal women are poorly investigated. The patients are at risk of developing sexual hormone deficiency and impaired fertility. This prospective cohort study addresses predictive parameters of ovarian reserve after chemotherapy.MethodsFifty-one premenopausal women (28–46 years) with primary breast cancer were included in the trial. All of them received anthracycline-based chemotherapy (n = 18), or combinations with taxanes (n = 30), or anthracycline-free chemotherapy (n = 3). Changes in hormone levels (LH, FSH, E2 and Anti-Müllerian hormone (AMH)), antral follicle count (AFC), and amenorrhea were determined before (V1), and 6, 12 and 24 months after the initiation of chemotherapy (V2-V4). Quality of life parameters were evaluated. The additional impact of parity, BMI, and smoking on ovarian reserve was also assessed.ResultsAFC and AMH fell very markedly after chemotherapy and did not return to pre-treatment levels until V4. A significant positive correlation was noted in AFC before and 1 year after chemotherapy. AMH levels at V2-V4 were significantly correlated with those registered at V1. AFC and AMH were negatively correlated with age. Continued smoking had a significant detrimental effect on AFC after 24 months. LH and FSH levels increased between V1 and V2 and fell at V3 and V4, but stayed above pre-chemotherapy values. Two years after the start of chemotherapy 31/51 patients were amenorrhoic while 17 resumed their menstrual cycle; this was not influenced by the type of chemotherapy or age. Non-smokers were 13 times more likely to resume their menstruation than smokers. Quality of life (QL) was significantly lower 6 months after the initiation of chemotherapy. QL at one and 2 years after chemotherapy did not differ significantly from pre-chemotherapy scores.ConclusionsOur study contributes to a better understanding and prediction of ovarian reserve in young early breast cancer patients undergoing chemotherapy. The data suggest that personal counseling in regard of the preservation of fertility should be offered especially to patients of a higher age, with low AMH levels or low follicle counts. Patients should be advised to stop smoking in order to enhance the likelihood of preserving their fertility.Electronic supplementary materialThe online version of this article (10.1186/s12885-017-3593-x) contains supplementary material, which is available to authorized users.

show abstract

“…In healthy females, after the age of 37-38 years, >90% of oocytes present at birth have already undergone atresia. Therefore, there are differences between the characterization of a young woman in oncology and gynecology (Kim et al, 2011;Lobo, 2005;Peccatori et al, 2012). The age-related fertility preservation options are not completely clear in current guidelines for oncologists, and may be very important because the value of early fertility preservation counseling for young cancer patient fully depends on it.…”

Section: Discussionmentioning

confidence: 99%

Systematic Review of Available Guidelines on Fertility Preservation of Young Patients with Breast Cancer

Haddadi

Muhammadnejad²,

Sadeghi-Fazel³

et al. 2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: Since the survival rate of breast cancer patients has improved, harmful effects of new treatment modalities on fertility of the young breast cancer patients has become a focus of attention. This study aimed to systematically review and critically appraise all available guidelines for fertility preservation in young breast cancer patients. Materials and Methods: Major citation databases were searched for treatment guidelines. Experts from relevant disciplines appraised the available guidelines. The AGREE II Instrument that includes 23 criteria in seven domains (scope and purpose of the guidelines, stakeholder involvement, rigor of development, clarity, applicability, editorial independence, and overall quality) was used to apprise and score the guidelines. Results: The search strategy retrieved 2,606 citations; 72 were considered for full-text screening and seven guidelines were included in the study. There was variability in the scores assigned to different domains among the guidelines. ASCO (2013), with an overall score of 68.0%, had the highest score, and St Gallen, with an overall score of 24.7%, had the lowest scores among the guidelines. Conclusions: With the promising survival rate among breast cancer patients, more attention should be given to include specific fertility preservation recommendations for young breast cancer patients.

show abstract

Fertility Preservation Methods in Breast Cancer

Cited by 12 publications

References 61 publications

Fertility in Women of Reproductive Age After Breast Cancer Treatment: Practice Patterns and Outcomes

Fertility in Women of Reproductive Age After Breast Cancer Treatment: Practice Patterns and Outcomes

Reduced ovarian reserve in young early breast cancer patients: preliminary data from a prospective cohort trial

Systematic Review of Available Guidelines on Fertility Preservation of Young Patients with Breast Cancer

Contact Info

Product

Resources

About